Patents by Inventor Norbert B. Ghyselinck

Norbert B. Ghyselinck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7074611
    Abstract: The invention relates to a method for the stable inversion of a DNA fragment upon recombinase-mediated rearrangements using two sets of two incompatible site-specific recombinase targeting sites (SSRTS) in the same order but in reverse orientation flanking the DNA fragment to be inverted. The invention also relates to a method for the stable inversion of the DNA fragment upon rearrangement mediated by a recombinase such as Cre recombinase. The invention also relates to a method for obtaining a transgenic cell of which at least one allele of a DNA sequence of interest is invalidated by a process of conditional deletion and the genome of which has a reporter gene inserted at the place of the DNA fragment deleted by the process of conditional deletion. A method to generate targeting sites to perform site-specific recombination mediated cassette exchange is also provided.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: July 11, 2006
    Assignee: GIE-Cerbn, Centre Europeen de Recherche en Biologie et en Medecine (GIE)
    Inventors: Pierre Chambon, Norbert B. Ghyselinck, Frank Schnutgen
  • Publication number: 20040244071
    Abstract: The invention relates to a method for the stable inversion of a DNA fragment upon recombinase-mediated rearrangements using two sets of two incompatible site-specific recombinase targeting sites (SSRTS) in the same order but in reverse orientation flanking said DNA fragment to be inverted. The invention also relates to a method for the stable inversion of said DNA fragment upon rearrangement mediated by a recombinase such as Cre recombinase. The invention also relates to a method for obtaining a transgenic cell of which at least one allele of a DNA sequence of interest is invalidated by a process of conditional deletion and the genome of which comprises a reporter gene inserted at the place of the DNA fragment deleted by said processor conditional deletion. The invention also concerns a method to generate targeting sites to perform site-specific recombination mediated cassette exchange. The corresponding vectors, host cells, and transgenic animals are claimed.
    Type: Application
    Filed: April 13, 2004
    Publication date: December 2, 2004
    Inventors: Pierre Chambron, Norbert B. Ghyselinck, Frank Schnutgen
  • Publication number: 20030159160
    Abstract: The invention relates to a method for the stable inversion of a DNA fragment upon recombinase-mediated rearrangements using two sets of two incompatible site-specific recombinase targeting sites (SSRTS) in the same order but in reverse orientation flanking said DNA fragment to be inverted. The invention also relates to a method for the stable inversion of said DNA fragment upon rearrangement mediated by a recombinase such as Cre recombinase. The invention also relates to a method for obtaining a transgenic cell of which at least one allele of a DNA sequence of interest is invalidated by a process of conditional deletion and the genome of which comprises a reporter gene inserted at the place of the DNA fragment deleted by said process of conditional deletion. The invention also concerns a method to generate targeting sites to perform site-specific recombination mediated cassette exchange. The corresponding vectors, host cells, and transgenic animals are claimed.
    Type: Application
    Filed: April 27, 2001
    Publication date: August 21, 2003
    Inventors: Pierre Chambon, Norbert B. Ghyselinck, Frank Schnutgen
  • Patent number: 6521814
    Abstract: The invention relates to methods for treatment of neurological disease by administering an agent which interacts with a retinoid receptor associated with the neurological disease. The invention is also related to a method of modulating dopamine receptor synthesis by introducing an agent that interacts with a retinoid receptor associated with the dopamine receptor synthesis. The invention is further related to a transgenic animal, e.g., mouse, and mammalian cell line, which is deficient in the normal synthesis of one or more receptors of RAR&agr;, &bgr;, &ggr; and RXR, and cell line thereof.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: February 18, 2003
    Assignees: Institut National de la Santa et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, Bristol-Myers Squibb Company
    Inventors: Pierre Chambon, Emiliana Borrelli, Norbert B. Ghyselinck, Valérie Dupé, Manuel Mark, Daniel Metzger